• Applications
  • Oncology

    How it works
    The leading challenge in therapeutic treatments for cancer is the accurate characterization of complex protein interactions under physiologically relevant conditions, consistent with the native protein and tumor environment. MDS overcomes these obstacles as an in-solution technology with the capacity to characterize interactions of drug candidates with their targets directly in cell lysates, lipid membranes, serum, or tissue homogenate.

    Cancer is a global health problem accounting for one in six global deaths, necessitating the need for new treatment approaches. Current shifts focus on targeted tumor therapies and personalized treatment, demanding effective characterization of complex interactions under native conditions that mimic the cancer environment. Microfluidic Diffusional Sizing (MDS) overcomes these challenges by measuring in-solution interactions via size changes, compatible with complex matrices and complex targets such as membrane proteins. When measuring membrane protein interactions, MDS provides binding affinity, concentration, and receptor expression data, in addition to the physical size measurements to verify stability of therapeutics alone and in-complex. This understanding, notably receptor expression, expedites clinical advancement and generates patient-specific data for therapeutic efficiency.

    Determine affinity and receptor expression levels of oncology relevant targets.
    Figure 1. A simple membrane protein assay workflow using MDS to determine the binding affinity, concentration, and receptor expression level of an oncology relevant membrane protein and therapeutic binding partner.
    Case Study
    Recruitment of phospholipase Cγ1 to the non-structural membrane protein pK15 of Kaposi Sarcoma-associated herpesvirus promotes its Src-dependent phosphorylation.
    Get started

    To study oncoprotein interactions in their native state in solution we recommend the following:

    Affinity, Size, Receptor Expression Levels, Occupancy
    Workflow specification and benefits:
    • 25 min run time   
    • KD range from pM to µM   
    • Amount of binding partner 1-30 µg (affinity dependent)   
    • Amount of labeled species 70 ng  
    • 12 µL of sample per triplicate   
    • Use of complex background e.g. serum, lysate, CSF  
    • Quick & easy to perform  

    Could we support your research? Get in touch